Chinese biopharma firm Pegbio nets $122m in pre-IPO round from YF Capital, Yingke, others

Chinese biopharma firm Pegbio nets $122m in pre-IPO round from YF Capital, Yingke, others

Photo by Brett Jordan on Unsplash

Pegbio, a Suzhou-based biopharmaceutical company that specialises in innovative drugs for diabetes and obesity, announced on Tuesday that it has secured around 800 million yuan ($122 million) in a pre-IPO round co-led by Jack Ma’s YF Capital, private equity firm Yingke PE, and life sciences-focussed investment firm TF Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter